Page 1

Announcement no . 04/2021 18 August 2021 9M 2020/21 Interim financial results , 9M 2020/21 1 October 2020 - 30 June 2021 • Coloplast Ostomy Care Continence Care Wound & Skin Care Interventional Urology Coloplast A / S Holtedam 1 DK - 3050 Humlebaek , Denmark Company reg . ( CVR ) no . 69749917 Coloplast delivered Q3 organic growth of 11 % and 33 % EBIT margin . Financial guidance narrowed Coloplast delivered 11 % organic growth in Q3 . Reported revenue in DKK was up by 9 % to DKK 4,835 million . Organic growth rates by business area in Q3 : Ostomy Care 4 % , Continence Care 5 % , Interventional Urology 82 % and Wound & Skin Care 17 % . • • • • • The Chronic Care business was positively impacted by improving underlying growth in Europe as well as a lower baseline . Growth was partly offset by lower growth in new patients in the US due to COVID - 19 , in especially Continence Care , as well as distributor destocking due to a prolonged period of lower growth in new patients . Ostomy Care delivered a softer quarter in Emerging markets due to tender phasing in the Middle East and Russia . The tenders are confirmed for delivery in Q4 . During Q3 , hospital activity increased as vaccines were rolled out and as a result growth in new patients within Ostomy Care normalised towards pre - COVID levels across markets . Growth in new patients within Continence Care is taking longer to normalise as expected , but the trend during Q3 was positive across markets . The Interventional Urology business delivered a strong quarter driven by broad - based recovery in elective procedures led by the US and Men's Health , as well as a lower baseline . The Wound and Skin Care business delivered a solid quarter . Wound Care alone delivered 20 % organic growth driven by Europe and China and strong contribution from the Biatain Silicone portfolio , as well as a lower baseline . EBIT was DKK 1,592 million , a DKK 224 million ( 16 % ) increase from last year , corresponding to an EBIT margin of 33 % which reflects efficiency gains and lower costs due to COVID - 19 , partly offset by continued commercial investments . • Diluted earnings per share ( EPS ) increased by 26 % to DKK 5.88 . 9M organic growth of 6 % and 33 % EBIT margin • Coloplast delivered 6 % organic growth year to date . Reported revenue in DKK was up by 3 % to DKK 14,326 million . Organic growth rates by business area year to date : Ostomy Care 5 % , Continence Care 4 % , Interventional Urology 22 % and Wound & Skin Care 6 % . • • EBIT before special items amounted to DKK 4,705 million , a 7 % increase from last year , corresponding to an EBIT margin before special items of 33 % against 31 % last year . ROIC after tax before special items was 43 % against 45 % last year , negatively impacted by last year's acquisition of Nine Continents Medical . Diluted earnings per share ( EPS ) before special items increased by 17 % to DKK 17.24 . 2020/21 financial guidance narrowed - organic growth expected in the lower end of the 7-8 % range and EBIT margin expected to be in the upper end of the 32-33 % range before special items • • • We now expect organic revenue growth in the lower end of the 7-8 % range at constant exchange rates . Reported growth in DKK is still expected to be 4-5 % . Reported EBIT margin before special items is now expected to be in the upper end of the 32-33 % range . After special items , the reported EBIT margin is now expected to be in the upper end of the 31-32 % range . Capital expenditure continues to be expected -DKK 1.1 billion . The effective tax rate is still expected to be -23 % . Conference call Coloplast will host a conference call on Wednesday , 18 August 2021 at 15.00 CEST . The call is expected to last about one hour . To actively participate in the Q & A session please call +45 3544 5577 , +44 3333 000 804 or +1 631 913 1422. The participant PIN code is 87004267 # Access the conference call webcast directly here : https://getvisualtv.net/strea m / ? coloplast - x9e5dfwgrq 1